Age-Associated Risk of 90-Day Postoperative Mortality After Cytoreductive Surgery for Advanced Ovarian Cancer
Open Access
- 1 July 2019
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 154 (7) , 669-671
Abstract
Surgical resection of all visible tumors is associated with improved long-term survival and is a critical component of primary therapy for advanced-stage ovarian cancer.1 However, cytoreductive surgery carries a substantial risk of complications and death.2 We describe associations between age and 90-day postoperative mortality after cytoreductive surgery and investigate if administrating neoadjuvant chemotherapy diminishes the age-associated risk of 90-day mortality.Keywords
This publication has 4 references indexed in Scilit:
- Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian CancerJournal of Clinical Oncology, 2016
- Thirty-Day Mortality After Primary Cytoreductive Surgery for Advanced Ovarian Cancer in the ElderlyObstetrics & Gynecology, 2011
- SELECTING THE NUMBER OF CHANGE-POINTS IN SEGMENTED LINE REGRESSION2009
- Cancer of the OvaryNew England Journal of Medicine, 2004